Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galderma Group AGXSWX:GALD +1.19%14 Debt-to-Equity is 0.34 as of Dec. 2025, which is 3% below its 10-year median of 0.35. GuruFocus rates XSWX:GALD with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 812 Drug Manufacturers companies, Galderma Group AG ranks worse than 56.65% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Galderma Group AG's Debt-to-Equity or its related term are showing as below:
XSWX:GALD'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.34 Med: 0.35 Max: 0.91
Current: 0.34
During the past 5 years, the highest Debt-to-Equity Ratio of Galderma Group AG was 0.91. The lowest was 0.34. And the median was 0.35.
XSWX:GALD's Debt-to-Equity is ranked worse than 56.65% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs XSWX:GALD: 0.34
Galderma Group AG (XSWX:GALD) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Galderma Group AG Debt-to-Equity Related Terms
Galderma Group AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALD vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (XSWX:GALD) has a Debt-to-Equity of 0.34 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Galderma Group AG and its competitors. This is near median its historical median of 0.35. Over the past decade, Galderma Group AG's Debt-to-Equity has ranged from 0.34 to 0.91. According to the industry distribution chart, Galderma Group AG ranks #460 out of 812 companies in the Drug Manufacturers industry, placing it in the top 56.7%.
Is Galderma Group AG's Debt-to-Equity too high?
Galderma Group AG's current Debt-to-Equity of 0.34 is near median its 10-year median of 0.35. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 0.91. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Galderma Group AG's value of 0.34 is 25.9% above this industry median. Based on the distribution chart, Galderma Group AG ranks #460 out of 812 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Galderma Group AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #460 out of 812 companies for Debt-to-Equity. This places Galderma Group AG in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Galderma Group AG's value of 0.34 is 25.9% above this benchmark. Historically, Galderma Group AG's own Debt-to-Equity has ranged from 0.34 to 0.91 over the past decade. While the company's 10-year median is 0.35 vs. the industry median of 0.27, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current Debt-to-Equity of 0.34 is 25.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current Debt-to-Equity is 0.34, which is near median its own 10-year median of 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Debt-to-Equity of 0.34. The current Debt-to-Equity is 0.34, which is near median its 10-year median of 0.35 and 25.9% above the Drug Manufacturers industry median of 0.27. Galderma Group AG's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Debt-to-Equity is 0.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
14GF Score
Get the complete analysis for XSWX:GALD
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 
